Logo image of ZBIO

ZENAS BIOPHARMA INC (ZBIO) Stock Fundamental Analysis

NASDAQ:ZBIO - Nasdaq - US98937L1052 - Common Stock - Currency: USD

7.83  +0.02 (+0.26%)

After market: 7.83 0 (0%)

Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to ZBIO. ZBIO was compared to 571 industry peers in the Biotechnology industry. ZBIO has a great financial health rating, but its profitability evaluates not so good. ZBIO does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year ZBIO has reported negative net income.
In the past year ZBIO has reported a negative cash flow from operations.
ZBIO Yearly Net Income VS EBIT VS OCF VS FCFZBIO Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2022 2023 -20M -40M -60M -80M -100M

1.2 Ratios

ZBIO has a better Return On Assets (-31.97%) than 65.54% of its industry peers.
ZBIO has a Return On Equity of -35.88%. This is in the better half of the industry: ZBIO outperforms 74.78% of its industry peers.
Industry RankSector Rank
ROA -31.97%
ROE -35.88%
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ZBIO Yearly ROA, ROE, ROICZBIO Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2022 2023 -50 -100 -150 -200

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for ZBIO so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ZBIO Yearly Profit, Operating, Gross MarginsZBIO Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2022 2023 -20 -40 -60

More info and screens

7

2. Health

2.1 Basic Checks

ZBIO does not have a ROIC to compare to the WACC, probably because it is not profitable.
ZBIO has about the same amout of shares outstanding than it did 1 year ago.
ZBIO has a worse debt/assets ratio than last year.
ZBIO Yearly Shares OutstandingZBIO Yearly Shares OutstandingYearly Shares Outstanding 2022 2023 10M 20M 30M
ZBIO Yearly Total Debt VS Total AssetsZBIO Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2022 2023 20M 40M 60M

2.2 Solvency

An Altman-Z score of 3.25 indicates that ZBIO is not in any danger for bankruptcy at the moment.
The Altman-Z score of ZBIO (3.25) is better than 75.67% of its industry peers.
ZBIO has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 3.25
ROIC/WACCN/A
WACC9.39%
ZBIO Yearly LT Debt VS Equity VS FCFZBIO Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2022 2023 0 20M -20M 40M -40M -60M

2.3 Liquidity

A Current Ratio of 8.95 indicates that ZBIO has no problem at all paying its short term obligations.
ZBIO has a Current ratio of 8.95. This is in the better half of the industry: ZBIO outperforms 76.20% of its industry peers.
A Quick Ratio of 8.95 indicates that ZBIO has no problem at all paying its short term obligations.
Looking at the Quick ratio, with a value of 8.95, ZBIO is in the better half of the industry, outperforming 76.38% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 8.95
Quick Ratio 8.95
ZBIO Yearly Current Assets VS Current LiabilitesZBIO Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2022 2023 20M 40M 60M

More info and screens

0

3. Growth

3.1 Past

ZBIO shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -299.25%.
The Revenue for ZBIO has decreased by -100.00% in the past year. This is quite bad
EPS 1Y (TTM)-299.25%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-203.82%
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-100%

3.2 Future

The Earnings Per Share is expected to decrease by -58.62% on average over the next years. This is quite bad
Based on estimates for the next years, ZBIO will show a very negative growth in Revenue. The Revenue will decrease by -19.70% on average per year.
EPS Next Y-703.1%
EPS Next 2Y-105.97%
EPS Next 3Y-58.62%
EPS Next 5YN/A
Revenue Next Year-100%
Revenue Next 2Y-41.42%
Revenue Next 3Y-19.7%
Revenue Next 5YN/A

3.3 Evolution

ZBIO Yearly Revenue VS EstimatesZBIO Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2022 2023 2024 2025 2026 10M 20M 30M 40M
ZBIO Yearly EPS VS EstimatesZBIO Yearly EPS VS EstimatesYearly EPS VS Estimates 2022 2023 2024 2025 2026 -2 -4 -6

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for ZBIO. In the last year negative earnings were reported.
Also next year ZBIO is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ZBIO Price Earnings VS Forward Price EarningsZBIO Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ZBIO Per share dataZBIO EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4 6 8

4.3 Compensation for Growth

A cheap valuation may be justified as ZBIO's earnings are expected to decrease with -58.62% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-105.97%
EPS Next 3Y-58.62%

More info and screens

0

5. Dividend

5.1 Amount

ZBIO does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ZENAS BIOPHARMA INC

NASDAQ:ZBIO (2/21/2025, 8:00:02 PM)

After market: 7.83 0 (0%)

7.83

+0.02 (+0.26%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-12 2024-11-12/bmo
Earnings (Next)N/A N/A
Inst Owners71.1%
Inst Owner Change-98.59%
Ins Owners1.05%
Ins Owner Change110.33%
Market Cap327.22M
Analysts87.27
Price Target32.47 (314.69%)
Short Float %10.89%
Short Ratio10.07
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-7.46%
PT rev (3m)-13.38%
EPS NQ rev (1m)1.74%
EPS NQ rev (3m)1.54%
EPS NY rev (1m)-0.58%
EPS NY rev (3m)3.11%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 0.91
P/tB 0.91
EV/EBITDA N/A
EPS(TTM)-3.19
EYN/A
EPS(NY)-3.95
Fwd EYN/A
FCF(TTM)-2.31
FCFYN/A
OCF(TTM)-2.31
OCFYN/A
SpS0
BVpS8.6
TBVpS8.6
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -31.97%
ROE -35.88%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 55.22%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 8.95
Quick Ratio 8.95
Altman-Z 3.25
F-Score4
WACC9.39%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-299.25%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-203.82%
EPS Next Y-703.1%
EPS Next 2Y-105.97%
EPS Next 3Y-58.62%
EPS Next 5YN/A
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-100%
Revenue Next Year-100%
Revenue Next 2Y-41.42%
Revenue Next 3Y-19.7%
Revenue Next 5YN/A
EBIT growth 1Y-522.95%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-442.2%
EBIT Next 3Y-101.61%
EBIT Next 5YN/A
FCF growth 1Y54.98%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y53.5%
OCF growth 3YN/A
OCF growth 5YN/A